Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib: A retrospective cohort study

In 2014, Joensuu and colleagues devised the first recurrence risk score (RRS) to identify the risk factors for gastrointestinal stromal tumor (GIST) recurrence. However, there are scarce data available on RRS effectiveness and efficiency. Therefore, we retrospectively analyzed clinical data to valid...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Jianwei, Zhao, Rui, Zheng, Xiaobo, Xu, Liangliang, Wang, Yong, Feng, Lei, Ren, Shengsheng, Wang, Peng, Zhang, Ming, Xu, Mingqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086542/
https://www.ncbi.nlm.nih.gov/pubmed/30024511
http://dx.doi.org/10.1097/MD.0000000000011400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086542/
https://www.ncbi.nlm.nih.gov/pubmed/30024511
http://dx.doi.org/10.1097/MD.0000000000011400

Ejemplares similares